Lizak G E, Grumet F C
Hum Immunol. 1983 Dec;8(4):265-71. doi: 10.1016/0198-8859(83)90053-8.
Sensitivity of the carboxyfluorescein diacetate (C-FDA) thrombocytotoxicity technique for the detection of antiplatelet antibodies has been enhanced by the addition of an anti-Kappa light chain antibody facilitation step. This new technique, KC-FDA, was compared with the platelet suspension immunofluorescence test (PSIFT) by titering platelet-reactive allo-anti-PlAl and anti-HLA antibodies. The results show that compared to PSIFT, KC-FDA is more sensitive for detecting platelet specific antibodies (PlAl), is more or equally sensitive for detecting other antibodies (HLA), and is significantly faster and easier to perform.
通过添加抗κ轻链抗体促进步骤，增强了用于检测抗血小板抗体的羧基荧光素二乙酸酯（C-FDA）血小板毒性技术的敏感性。通过滴定血小板反应性同种异体抗PlAl和抗HLA抗体，将这项新技术KC-FDA与血小板悬液免疫荧光试验（PSIFT）进行了比较。结果表明，与PSIFT相比，KC-FDA在检测血小板特异性抗体（PlAl）方面更敏感，在检测其他抗体（HLA）方面同样敏感或更敏感，并且操作明显更快、更简便。
